Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Brain metastases: the HER2 paradigm.

Nancy U Lin1, Eric P Winer

  • 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|March 17, 2007
PubMed
Summary

Central nervous system (CNS) metastases are increasing in HER2-positive breast cancer patients. New systemic therapies offer hope for managing brain metastases and improving outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tumor characteristics associated with tomosynthesis versus digital mammography in older women with screen-detected breast cancer.

Breast cancer research and treatment·2026
Same author

Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab for Stage II to III, ERBB2-Positive Breast Cancer: A Secondary Analysis of the DAPHNe Trial.

JAMA oncology·2026
Same author

Longitudinal multi-platform profiling reveals temporal dynamics of HER2, TROP2, PD-L1 and tumor-infiltrating lymphocytes in triple-negative breast cancer.

medRxiv : the preprint server for health sciences·2026
Same author

Pregnancy history, recency of childbirth, and outcomes in young women with early-stage breast cancer.

Journal of the National Cancer Institute·2026
Same author

A phase II study of atezolizumab in combination with stereotactic radiation for patients with triple-negative breast cancer and brain metastasis.

Breast cancer research and treatment·2026
Same author

TBCRC 048 (Olaparib Expanded) Expansion Cohorts: Phase II Study of Olaparib Monotherapy for Patients With Metastatic Breast Cancer With Germline Mutations in <i>PALB2</i> or Somatic Mutations in <i>BRCA1</i> or <i>BRCA2</i>.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Area of Science:

  • Neuro-oncology
  • Medical oncology
  • Epidemiology

Background:

  • Central nervous system (CNS) metastases affect 100,000-170,000 cancer patients annually in the U.S.
  • Approximately 20% of CNS metastases originate from breast cancer.
  • Improved systemic therapies have increased patient survival, making CNS metastases a critical concern.

Purpose of the Study:

  • Review changes in the epidemiology and natural history of brain metastases in HER2-positive breast cancer.
  • Discuss the increasing incidence and potential causes of CNS disease in this population.
  • Explore therapeutic challenges and opportunities for treating CNS metastases.

Main Methods:

  • Review of epidemiological data over the past decade.
  • Analysis of changes in the natural history of HER2-positive breast cancer brain metastases.
  • Exploration of current and emerging systemic treatment strategies.

Main Results:

  • An apparent increase in CNS disease among women with HER2-positive breast cancer compared to historical controls.
  • CNS metastases represent a significant challenge, impacting prognosis and quality of life.
  • Advances in systemic therapies, including chemotherapy and targeted treatments, are being explored.

Conclusions:

  • CNS metastases are an increasing concern in HER2-positive breast cancer, necessitating improved treatment strategies.
  • Understanding the evolving epidemiology and natural history is crucial for developing effective interventions.
  • New systemic approaches hold promise for managing brain metastases and improving patient outcomes.

Related Experiment Videos